相关实验视频
Updated: Sep 14, 2025

07:27
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
24.8K
儿童心力衰竭:当前的方法和治疗方法
Benjamin A Olsen1, Shelley D Miyamoto2
1Department of Pediatrics, University of Colorado Graduate Medical Education, 13123 E. 16th Ave, Aurora, CO 80045.
JHLT open
|July 23, 2025
概括
儿童心力衰竭 (HF) 带来了独特的挑战,死亡率高于成人. 本综述探讨了当前的儿科HF治疗方法以及改善患者治疗结果的新策略.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 心血管研究研究心血管研究
- 翻译医学是一种翻译医学.
背景情况:
- 儿童心力衰竭 (HF) 是一种复杂的疾病,与成人心力衰竭相比,其死亡率和资源使用率更高.
- 儿童的心肌衰竭涉及独特的病理生理机制,与成人不同,影响治疗疗效.
- 现有的HF治疗指南主要基于成人数据,儿童特异性证据有限.
研究的目的:
- 审查目前儿童心力衰竭的诊断和治疗策略.
- 讨论儿科HF的新治疗方法和新兴技术.
- 突出挑战和未来方向,以改善儿科HF患者的治疗结果.
主要方法:
- 关于儿科心力衰竭管理的综合文献综述.
- 对诊断方式的分析,包括成像,实验室和功能研究.
- 评估药物和非药物治疗策略,包括先进疗法.
主要成果:
- 儿科HF诊断依赖于多模式成像,实验室测试和专业研究.
- 目前的药理疗法是根据成人指导方针进行的,往往缺乏直接的儿科证据.
- 针对儿科特异性HF病理生理学的新疗法正在开发中.
结论:
- 由于独特的疾病机制,儿科HF需要量身定制的方法.
- 新兴的疗法和技术为改善儿科HF结果提供了希望.
- 合作努力和公平的护理提供对于推进儿科HF管理至关重要.
相关概念视频
Heart Failure V: Medical Management
26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26
Heart Failure VI: Adjunct Therapies
29
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
29
Cardiomyopathy V: Interprofessional Care
35
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
35
Heart Failure VII: Nursing Interventions
140
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
140
Heart Failure IV: Classification and Diagnostic Evaluation
33
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
33
Cardiomyopathy II: Dilated Cardiomyopathy
23
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
23

